I recently bought Neurocrine Biosciences, Inc. (NASDAQ: $NBIX). As a disclosure, I consider this to be a highly speculative investment. Perform your own due diligence.
Snapshot for Neurocrine Biosciences, Inc.
Sector: Healthcare
Industry: System-Specific Biopharmaceuticals
Country: USA
Current Price: $96.03
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).
Financial Health for Neurocrine Biosciences, Inc.
Altman Z-Score: 9.64
Financial Health: SAFE
Revenue Analysis for Neurocrine Biosciences, Inc.
Regressed Revenue Growth: 34.70%
Based on historical valuations and revenue, the present value for Neurocrine Biosciences, Inc. is:
Bearish Case: $241.41
Bullish Case: $611.94
Income Analysis for Neurocrine Biosciences, Inc.
Regressed Net Income Growth: 29.85%
Based on historical valuations and net income, the present value for Neurocrine Biosciences, Inc. is:
Bearish Case: $84.37
Bullish Case: $6,399.89
Free Cash Flow Analysis for Neurocrine Biosciences, Inc.
Cost of Equity: 8.00%
Weighted Average Cost of Capital: 6.59%
Based on sensitivity analysis, the fair value for Neurocrine Biosciences, Inc. is:
Bearish Case: $118.78
Bullish Case: $180.02
Dividend Analysis for Neurocrine Biosciences, Inc.
Current Yield: 0.00%
Historical Yield: 0.00%
Based on historical dividends, the fair value for Neurocrine Biosciences, Inc. is: $0.00
Final Ratings for Neurocrine Biosciences, Inc.
Growth Rating: 5-Star
Income Rating: 1-Star
[link] [comments] https://www.reddit.com/r/stocks/comments/14zfcac/quantitative_analysis_of_neurocrine_biosciences/
Accedi per aggiungere un commento
Altri post in questo gruppo
Please use this thread to discuss your portfolio, learn of other stock tickers, and help out users by giving constructive criticism.
Why quarterly? Public comp
When you sell a stock to buy another stock, do you prefer to set the estimated amount of the capital gains taxes aside in a money market or do you think it better to
Saving for retirement is crucial, but relying solely on a 401(k) might not be enough due to high inflation. Consider investing in growth stocks, especially in the tec
I’m think this is not a good investment as there is no chatter at all on the 52 week low. They are involved in a class action lawsuits by investors and credit card co
Sorry if this is the wrong sub. Let’s say I had $1 million in VOO but I wanted to sell half of it to buy SCHD. It would suck to pay taxes on $500k. So how would you g
Hey guys, I did a deep dive into Crocs. In this analysis, I will do a brief breakdown of the company and go over some quantitative data, qualitative data and estimate
